Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 4:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Metformin hydrochloride Clear all
Terminated Phase 2 Interventional Results available

Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)

NCT02531308
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Metformin, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, pegfilgrastim
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 29, 2026, 4:48 PM EDT
Completed Phase 3 Interventional Results available

Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

NCT04029480
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ertugliflozin 5 mg, Ertugliflozin 15 mg, Placebo to ertugliflozin 15 mg, Placebo to ertugliflozin 5 mg, Insulin, Metformin
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
10 Years to 17 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 29, 2026, 4:48 PM EDT
Terminated Phase 3 Interventional

Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes

NCT00427154
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
rosiglitazone, inhaled human insulin, metformin, glimepiride
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
103
States / cities
Hueytown, Alabama • Ozark, Alabama • Tuscaloosa, Alabama + 95 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Sep 29, 2026, 4:48 PM EDT
Terminated Phase 1 Interventional

Metformin and Congenital Nephrogenic Diabetes Insipidus

NCT02460354
View directory record Official record
Conditions
Diabetes Insipidus
Interventions
Metformin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 29, 2026, 4:48 PM EDT
Completed Phase 1 Interventional

A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.

NCT01017302
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Placebo, RO5095932
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 29, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years

NCT07216131
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD0780, Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 29, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Three New Ideas to Protect Special Forces From the Stress of High Altitude

NCT02463357
View directory record Official record
Conditions
Mountain Sickness
Interventions
Quercetin, Nifedipine extended release, Methazolamide, Metformin, Placebo, Nitrite
Dietary Supplement · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Alma, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Sep 29, 2026, 4:48 PM EDT
Not listed No phase listed Observational

Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)

NCT03627039
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
SGLT2, Metformin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Sep 29, 2026, 4:48 PM EDT
Terminated Phase 1 Interventional

Managing Chronic Tendon Pain by Metformin

NCT06100822
View directory record Official record
Conditions
Tendinopathy, Chronic Pain, Achilles Tendinopathy
Interventions
Metformin, Placebo
Drug
Lead sponsor
James Wang
Other
Eligibility
18 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 29, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Results available

A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin

NCT00386100
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Avandamet 6 mg/1500 mg (ttd), Avandamet 4 mg/1000 mg (ttd), Avandamet 2 mg/500 mg (ttd), Avandamet 8 mg/ 2000 mg (ttd), Metformin 500 mg (ttd), Metformin 1000 mg (ttd), Metformin 1500 mg (ttd), Metformin 2000 mg (ttd)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
71
States / cities
Tuscaloosa, Alabama • Gilbert, Arizona • Glendale, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Sep 29, 2026, 4:48 PM EDT
Completed Phase 1 Interventional

A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients

NCT01221519
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, High Blood Sugar
Interventions
AZD1656
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 18, 2012 · Synced Sep 29, 2026, 4:48 PM EDT
Recruiting Phase 2 Interventional

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

NCT04114136
View directory record Official record
Conditions
Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer, Gastric Adenocarcinoma, HNSCC, Esophageal Adenocarcinoma, Microsatellite Instability-High Solid Malignant Tumor
Interventions
Nivolumab or Pembrolizumab (dependent upon approved indication), Metformin, Rosiglitazone
Drug
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 29, 2026, 4:48 PM EDT
Completed Phase 3 Interventional Results available

Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.

NCT00570739
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hypercholesterolemia, Pre-diabetes
Interventions
Metformin HCl and Colesevelam Placebo, Metformin HCl tablets and Colesevelam tablets, Colesevelam placebo, Colesevelam
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 79 Years
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Birmingham, Alabama • Los Gatos, California • Tarzana, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2010 · Synced Sep 29, 2026, 4:48 PM EDT
Completed Phase 3 Interventional

Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes

NCT00138567
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 78 Years
Enrollment
530 participants
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 29, 2026, 4:48 PM EDT
Not yet recruiting Early Phase 1 Interventional

Metformin and ACLR Muscle Recovery

NCT07699367
View directory record Official record
Conditions
Atrophy, Inflammation, Weakness, Muscle
Interventions
Metformin, Placebo
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 29, 2026, 4:48 PM EDT
Completed Phase 3 Interventional Results available

Diabetes Prevention Program Outcomes Study

NCT00038727
View directory record Official record
Conditions
Diabetes Mellitus, Cancer, CVD
Interventions
DPPOS Group Lifestyle, Metformin, DPPOS Boost Lifestyle, Intensive Lifestyle Group Session
Behavioral · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
25 Years and older
Enrollment
2,779 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2022
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 29, 2026, 4:48 PM EDT
Terminated Not applicable Interventional Results available

Validation of Machine Learning Based Personalized Nutrition Algorithm to Reduce Postprandial Glycemic Excursions Among North American Individuals With Newly Diagnosed Type 2 Diabetes

NCT03053518
View directory record Official record
Conditions
Type2 Diabetes
Interventions
Abbott Freestyle Libre Pro, LifeStyle
Device · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2020 · Synced Sep 29, 2026, 4:48 PM EDT
Recruiting Phase 2 Interventional

Remote Cognitive Assessment and Wearable Device While Assessing the Impact of Metformin in Patients With History of Cranial Radiation Therapy

NCT06377696
View directory record Official record
Conditions
Malignant Brain Neoplasm
Interventions
Best Practice, Medical Device Usage and Evaluation, Metformin, Neurocognitive Assessment, Questionnaire Administration
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 29, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

NCT02106923
View directory record Official record
Conditions
Healthy
Interventions
1 tablet Empagliflozin/2 tablets Metformin XR, 10 mg Empagliflozin/1000 mg Metformin XR, 1 tablet 10 mg Empagliflozin/3 tablets Metformin XR, 2 tablets 5 mg Empagliflozin/750 Metformin XR
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Sep 29, 2026, 4:48 PM EDT
Completed Phase 3 Interventional Results available

A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes

NCT03214380
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec, Metformin, SGLT2 inhibitor
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
933 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
32
States / cities
Fresno, California • La Mesa, California • Lancaster, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Sep 29, 2026, 4:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma

NCT02949700
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Metformin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 29, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects

NCT03061981
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Metformin, DA-1241
Drug
Lead sponsor
Dong-A ST Co., Ltd.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Sep 29, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)

NCT07158411
View directory record Official record
Conditions
Healthy Participants
Interventions
Vimseltinib, Metformin
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 29, 2026, 4:48 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer

NCT06030622
View directory record Official record
Conditions
Pancreatic Cancer Metastatic
Interventions
Gemcitabine and C3 (Metformin, Simvastatin, and Digoxin), C3 (Metformin, Simvastatin, and Digoxin) only
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 29, 2026, 4:48 PM EDT